Objective: To explore a tumor peptide imaging agent Arginine-Arginine-Leucine (Tyr-Cys-Gly-Gly-Arg-ArgLeu-Gly-Gly-Cys, tripeptide RRL [tRRL]) that targeted to tumor cells and tumor-derived endothelial cells (TDECs) and primarily investigate the possible relationship between tRRL and vascular endothelial growth factor receptor 2 (VEGFR-2).
INTRODUCTION
survive and initiate the metastases of tumors [1, 2] . Imaging techniques, including modern nuclear medicine such as positron emission computed tomography (PET), play important roles in tumor clinical diagnosis and treatment. Recently, molecular imaging, especially single-photon emission computed tomography (SPECT) imaging, is being used to explore new areas [3] .
Despite the progress in research into cancer diagnosis and treatment, limitations of imaging methods with good sensitivity and specificity of imaging agents used in the clinic are still challenging. Because angiogenesis is an essential step for tumor growth and initiation of metastasis [4] , researchers have devoted enormous energy to the discovery of angiogenic factors [5, 6] and developed angiogenesis imaging methods for early diagnosis, optimal treatment for individual patients and predicting subsequent clinical response [7] [8] [9] [10] [11] . To meet the demand for rapid development and potential clinical application of anti-angiogenesis tumor therapy, developing noninvasive imaging methods with a targeted imaging agent specifically binding with tumor vascular endothelial cells is desirable.
Radiolabeled peptides attract increasing interest in imaging angiogenesis and targeted radiotherapy of malignant tumors [12] [13] [14] [15] [16] . These small-molecule agents could gain access to target sites more easily than monoclonal antibodies [17] . Special emphasis has been devoted to the development of peptides labeled with radionuclides. Ruoslahti and others identified various peptides with binding specificity to angiogenic endothelium and endothelial cells from various organs [18, 19] . Brown, et al. identified the nonapeptide sequence motif Cys-Gly-Gly-Arg-Arg-Leu-Gly-GlyCys (RRL) with binding specificity for tumor-derived endothelial cells (TDECs) by use of FliTrx™ [20] . Further ultrasonic imaging after microbubbles conjugated RRL (MB-RRL) injection showed that ultrasonography of tumors was enhanced with MB-RRL [21] . Other researchers conjugated 2 near-infrared dyes (Alexa 680, 800) to RRL peptide and found injected tumor but not any other site or organ with an appreciable image signal in human PC3 prostate tumor-bearing mice or transgenic mice with prostate cancer [22] . In our previous study, we designed and synthesized decapeptide tRRL [23] .
In this study, we explored the association of tRRL to tumor cells and TDECs and the possible relationship between tRRL and vascular endothelial growth factor receptor 2 (VEGFR-2). We aimed to develop a molecular imaging agent with high sensitivity and specificity to visualize tumors in vivo for a potential carrier for radioimmunotherapy.
MATERIALS AND METHODS

Peptide Design and Synthesis
The sequence of tRRL was redesigned and synthesized as described previously [23] . Tyrosine was added to the amino terminus of RRL and labeled by iodine-131. The new sequence was (Tyr)-Cys-Gly-GlyArg-Arg-Leu-Gly-Gly-Cys (tRRL), and the control peptide sequence was (Tyr)-Cys-Gly-Gly-Gly-Gly-GlyGly-Gly-Cys (tGGG). One part of the synthetic tRRL compounds was conjugated with fluorescein isothiocyanate (FITC) during synthesis. The lyophilized peptide was stored at 20  C.
Radiolabeling with Iodine-131
Decapeptide tRRL was labeled with 131 I by electrophilic radioiodination by use of chloramine-T as oxidizing agent, essentially as described previously [23] . Briefly, 50 μg tRRL was labeled with 37 MBq [ 131 I]Na. After a 2-min reaction, the mixture was diluted with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin and purified by a sizeexclusion chromatography column (Sephadex G-10 M). The 131 I peak eluting from the column was collected, and radioactivity was measured.
In Vitro Studies Cell Lines and Regents
HepG2 (human hepatocellular liver carcinoma cell line), B16 (mouse melanoma cell line), SKOV3 (human ovarian carcinoma cell line), EOMA (mouse endothelioma cell line) (10th passage), HK-2 (immortalized proximal tubule epithelial cell line) (17th to 19th passage), and human umbilical vein endothelial cells (HUVECs) from the American Type Culture Collection were maintained as recommended. THP-1 cells (human acute monocytic leukemia cell line) (10th passage) and human aortic endothelial cells (HAECs) (2nd to 5th passage) were gifts from Professor Chun-yan Zhou (Peking University Health Science Center, Department of Biochemistry and Molecular Biology, Beijing, China). EOMA, HUVECs and HAECs were cultured in extracellular matrix medium containing 5% fetal bovine serum (SclenCell), 100 μg/ml streptomycin, 100 U/ml penicillin, and 1% endothelial cell growth supplement (SclenCell). HepG2, THP-1 and HK-2 cells were maintained in DMEM/High Glucose medium containing 10% fetal bovine serum (GIBCO), 2 mmol/L glutamine, and 4,500 mg/L glucose. SKOV3 and B16 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1 mmol/L glutamine. All commercially available chemical reagents were used without further purification. In each independent experiment, HUVECs were used before the fifth passage. All cells were incubated at 37ºC in a humidified atmosphere containing 5% CO2. The experiments were performed with cells in the logarithmic phase of growth.
I-tRRL Binding Experiment
HUVECs and B16, HepG2 and HK-2 cells were cultured in 24-well plates (5×10 4 per well). Cells were starved for 16 h in serum-free medium, then cocultured with medium containing 37 kBq 131 I-tRRL per well. We harvested the medium (non-uptake
